Details

Autor(en) / Beteiligte

• Rubin, Lewis J
• Badesch, David B
• Barst, Robyn J
• Galiè, Nazzareno
• Black, Carol M
• Keogh, Anne
• Pulido, Tomas
• Frost, Adaani
• Roux, Sébastien
• Leconte, Isabelle
• Landzberg, Michael
• Simonneau, Gérald

Titel

Bosentan Therapy for Pulmonary Arterial Hypertension

Ist Teil von

• The New England journal of medicine, 2002-03, Vol.346 (12), p.896-903

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2002

Quelle

MEDLINE

Beschreibungen/Notizen

• Endothelin-1, a potent vasoconstrictor and smooth-muscle mitogen, may have a role in the pathogenesis of pulmonary hypertension. The therapeutic efficacy of bosentan, an endothelin-receptor antagonist, was evaluated in this randomized clinical trial. Bosentan at a dose of 125 mg twice daily improved exercise capacity and functional class. Treatment with an endothelin-receptor antagonist improved exercise capacity. Pulmonary arterial hypertension is a debilitating disease characterized by an increase in pulmonary vascular resistance leading to right ventricular failure and death. 1 Pulmonary arterial hypertension with no apparent cause is termed primary pulmonary hypertension. Pulmonary arterial hypertension can also develop in up to 50 percent of patients with scleroderma. 2 , 3 The limited oral treatment options include long-term anticoagulant therapy 4 , 5 and therapy with calcium-channel blockers; the latter improve survival in a limited number of patients. 5 Beneficial effects have been reported with continuous intravenous infusion of epoprostenol (prostacyclin), but this treatment has drawbacks. 6 , 7 The efficacy of epoprostenol analogues that can . . .